Innate Pharma (IPHA) Stock Forecast & Price Target

Compare

130 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IPHA Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Innate

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IPHA Stock 12 Month Forecast

Average Price Target

$6.50

▲(269.32% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Innate Pharma in the last 3 months. The average price target is $6.50 with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 269.32% change from the last price of $1.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","2.25":"$2.25","4.5":"$4.5","6.75":"$6.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.25,4.5,6.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.433846153846154,2.897692307692308,3.3615384615384616,3.8253846153846154,4.28923076923077,4.753076923076923,5.216923076923077,5.680769230769231,6.144615384615385,6.608461538461539,7.072307692307692,7.536153846153846,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.3184615384615386,2.666923076923077,3.0153846153846153,3.363846153846154,3.712307692307692,4.060769230769231,4.40923076923077,4.757692307692308,5.1061538461538465,5.454615384615384,5.803076923076923,6.151538461538462,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.97,2.203076923076923,2.436153846153846,2.6692307692307695,2.9023076923076925,3.1353846153846154,3.3684615384615384,3.6015384615384614,3.8346153846153848,4.067692307692308,4.300769230769231,4.533846153846154,4.766923076923077,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.15,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$8.00

Average Price Target$6.50

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Swayampakula Ramakanth

H.C. Wainwright

Buy

184.09%

Upside

Upgraded

10/28/25

Innate Pharma upgraded to Buy from Neutral at H.C. WainwrightInnate Pharma upgraded to Buy from Neutral at H.C. Wainwright

Christopher Liu

Lucid Capital

Buy

354.55%

Upside

Initiated

10/23/25

Innate Pharma initiated with a Buy at Lucid CapitalInnate Pharma initiated with a Buy at Lucid Capital

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

―

Hold

―

Reiterated

10/08/25

Goldman Sachs Keeps Their Hold Rating on Innate Pharma (IPHA)

Daina Graybosch

Leerink Partners

$10→$2

Hold

13.64%

Upside

Downgraded

09/18/25

Innate Pharma's Strategic Shift and Financial Challenges Lead to Hold Rating

Justin Zelin

BTIG

Buy

354.55%

Upside

Reiterated

09/17/25

Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Innate Pharma (NASDAQ: IPHA)We see this reset as prudent and value accretive, concentrating resources on its highest ROI programs with clear differentiation and upcoming catalysts: IPH4502 FIH data in 1H26, monalizumab pivotal PACIFIC-9 data in 2H26, and lacutamab ph3 initiation in 2026. We reiterate our Buy rating and $8 PT, as we believe the streamlined portfolio sharpens the story and maximizes value creation for shareholders ahead of key catalysts.

Sean Lee

Citi

$11.5

Buy

553.41%

Upside

Reiterated

01/17/25

Citi Keeps Their Buy Rating on Innate Pharma (IPHA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Swayampakula Ramakanth

H.C. Wainwright

Buy

184.09%

Upside

Upgraded

10/28/25

Innate Pharma upgraded to Buy from Neutral at H.C. WainwrightInnate Pharma upgraded to Buy from Neutral at H.C. Wainwright

Christopher Liu

Lucid Capital

Buy

354.55%

Upside

Initiated

10/23/25

Innate Pharma initiated with a Buy at Lucid CapitalInnate Pharma initiated with a Buy at Lucid Capital

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

―

Hold

―

Reiterated

10/08/25

Goldman Sachs Keeps Their Hold Rating on Innate Pharma (IPHA)

Daina Graybosch

Leerink Partners

$10→$2

Hold

13.64%

Upside

Downgraded

09/18/25

Innate Pharma's Strategic Shift and Financial Challenges Lead to Hold Rating

Justin Zelin

BTIG

Buy

354.55%

Upside

Reiterated

09/17/25

Sean Lee

Citi

$11.5

Buy

553.41%

Upside

Reiterated

01/17/25

Citi Keeps Their Buy Rating on Innate Pharma (IPHA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innate Pharma

1 Month

xxx

Success Rate

7/16 ratings generated profit

Average Return

-1.58%

upgraded a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 43.75% of your transactions generating a profit, with an average return of -1.58% per trade.

3 Months

xxx

Success Rate

5/16 ratings generated profit

Average Return

-0.68%

upgraded a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 31.25% of your transactions generating a profit, with an average return of -0.68% per trade.

1 Year

Swayampakula RamakanthH.C. Wainwright

Success Rate

4/16 ratings generated profit

Average Return

-10.81%

upgraded a buy rating 2 months ago

Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -10.81% per trade.

2 Years

xxx

Success Rate

3/16 ratings generated profit

Average Return

-14.75%

upgraded a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 18.75% of your transactions generating a profit, with an average return of -14.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IPHA Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IPHA has received 3 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. IPHA average Analyst price target in the past 3 months is 6.50.

Each month's total comprises the sum of three months' worth of ratings.

IPHA Financial Forecast

IPHA Earnings Forecast

Next quarter’s earnings estimate for IPHA is -$0.14 with a range of -$0.14 to -$0.14. The previous quarter’s EPS was -$0.30. IPHA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.

IPHA Sales Forecast

Next quarter’s sales forecast for IPHA is $2.55M with a range of $2.55M to $2.55M. The previous quarter’s sales results were $1.83M. IPHA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.

IPHA Stock Forecast FAQ

What is IPHA’s average 12-month price target, according to analysts?

Based on analyst ratings, Innate Pharma’s 12-month average price target is 6.50.

What is IPHA’s upside potential, based on the analysts’ average price target?

Innate Pharma has 269.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IPHA a Buy, Sell or Hold?

Innate Pharma has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is Innate Pharma’s price target?

The average price target for Innate Pharma is 6.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.00 ,the lowest forecast is $5.00. The average price target represents 269.32% Increase from the current price of $1.76.

What do analysts say about Innate Pharma?

Innate Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of IPHA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Innate Pharma (IPHA) Stock Forecast & Price Target

IPHA Analyst Ratings

IPHA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Innate Pharma

IPHA Analyst Recommendation Trends

IPHA Financial Forecast

IPHA Earnings Forecast

IPHA Sales Forecast

IPHA Stock Forecast FAQ

Detailed List of Analyst Forecasts